BDBM111123 US10017516, Compound 2::US9682983, 2

SMILES C[C@H]1CNC[C@@H](C)N1c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12

InChI Key InChIKey=SHWKNOUREYUNBF-KDURUIRLSA-N

Data  20 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 20 hits for monomerid = 111123   

TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  5.80nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetActivin receptor type-1(Homo sapiens (Human))
National Center For Advancing Translational Sciences

Curated by ChEMBL
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  9nMAssay Description:Inhibition of ALK2 (unknown origin) using Ulight topo IIa (Thr 1342) peptide as substrate preincubated for 10 mins followed by substrate addition and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  9.10nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetActivin receptor type-1B(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  556nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  1.68E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  213nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  5.80nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetActivin receptor type-1(Homo sapiens (Human))
National Center For Advancing Translational Sciences

Curated by ChEMBL
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  10nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  9.10nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetActivin receptor type-1B(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  556nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  1.68E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  213nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetActivin receptor type-1(Homo sapiens (Human))
National Center For Advancing Translational Sciences

Curated by ChEMBL
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  8.60nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  6.5nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetActivin receptor type-1B(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  110nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  330nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  226nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  7nMAssay Description:Inhibition of ALK3 (unknown origin) using Ulight topo IIa (Thr 1342) peptide as substrate preincubated for 10 mins followed by substrate addition and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetActivin receptor type-1(Homo sapiens (Human))
National Center For Advancing Translational Sciences

Curated by ChEMBL
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  10nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent